MacroGenics has expanded its license agreement with Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates – ADCs -. The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2B, plus tiered low to high single-digit royalties on potential net sales of any resulting products. MacroGenics currently has the option to pursue up to seven ADC programs under the expanded deal, which includes three programs from the original collaboration. Under the original licensing agreement, MacroGenics gained access to Synaffix’s clinical stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads, each designed to enable ADCs with best-in-class efficacy and tolerability. These may be combined with MacroGenics’ proprietary antibody and bispecific DART platform technologies to generate next-generation ADCs.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MGNX:
- MacroGenics informs investors of no exposure to Silicon Valley Bank
- MacroGenics price target raised to $17 from $15 at Stifel
- MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
- MacroGenics announces sale of TZIELD royalty interest for up to $200M
- MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call